UTHR - United Therapeutics Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
118.65
-0.20 (-0.17%)
At close: 4:00PM EDT

118.65 0.00 (0.00%)
After hours: 6:35PM EDT

Stock chart is not supported by your current browser
Previous Close118.85
Open119.30
Bid118.45 x 1300
Ask118.56 x 1000
Day's Range118.25 - 120.22
52 Week Range100.06 - 130.00
Volume190,816
Avg. Volume368,748
Market Cap5.188B
Beta (3Y Monthly)0.80
PE Ratio (TTM)8.86
EPS (TTM)13.39
Earnings DateApr 30, 2019 - May 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est126.00
Trade prices are not sourced from all markets
  • MannKind or Akebia: Who’s Expected to Report Faster EPS Growth?
    Market Realist4 days ago

    MannKind or Akebia: Who’s Expected to Report Faster EPS Growth?

    MannKind or Akebia: Which Is a Better Biotech Pick This Month?(Continued from Prior Part)Financial performance In the fourth quarter, MannKind Corporation (MNKD) reported revenue of $16.03 million, a YoY (year-over-year) rise of 253.91%. According

  • PR Newswire8 days ago

    United Therapeutics Corporation to Present at Oppenheimer 29th Annual Healthcare Conference

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., March 12, 2019 /PRNewswire/ -- United Therapeutics Corporation (UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the Oppenheimer 29th Annual Healthcare Conference in New York City. The presentation will take place on Tuesday, March 19, 2019, at 1:35 PM Eastern Time, and can be accessed via a live webcast on the United Therapeutics website at http://www.unither.com under the "Investors" tab in the "Events and Presentations" section.

  • Update: United Therapeutics (NASDAQ:UTHR) Stock Gained 16% In The Last Five Years
    Simply Wall St.8 days ago

    Update: United Therapeutics (NASDAQ:UTHR) Stock Gained 16% In The Last Five Years

    United Therapeutics Corporation (NASDAQ:UTHR) shareholders might be concerned after seeing the share price drop 13% in the last week. But the silver lining is the stock is up over fiveRead More...

  • Zacks Small Cap Research14 days ago

    MNKD: A Head Start to 2019; Q4 and Annual 2018 Earnings Results

    The results for Q4 and the full year 2018 from MannKind Corp. (MNKD) were a pleasant surprise. MNKD also received a milestone payment of $10 million, which reflects $6.4M under the United Therapeutics (UTHR) license agreement, $3.8M from the UT research agreement and $0.1M from the Cipla marketing and distribution agreement. On the earnings call, management shared results related to Afrezza’s quarterly prescription growth since 2017.

  • PR Newswire16 days ago

    United Therapeutics Corporation To Present At Cowen And Company 39th Annual Health Care Conference

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., March 4, 2019 /PRNewswire/ -- United Therapeutics Corporation (UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company's business at the Cowen and Company 39th Annual Health Care Conference in Boston, Massachusetts. The presentation will take place on Monday, March 11, 2019, at 4:10 PM Eastern Time, and can be accessed via a live webcast on the United Therapeutics website at http://www.unither.com under the "Investors" tab in the "Events and Presentations" section.

  • Thomson Reuters StreetEvents18 days ago

    Edited Transcript of UTHR earnings conference call or presentation 27-Feb-19 2:00pm GMT

    Q4 2018 United Therapeutics Corp Earnings Call

  • United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates
    Zacks19 days ago

    United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates

    United Therapeutics (UTHR) beats estimates for both earnings and sales in the fourth quarter. Stock up.

  • United Therapeutics Corp (UTHR) Q4 2018 Earnings Conference Call Transcript
    Motley Fool20 days ago

    United Therapeutics Corp (UTHR) Q4 2018 Earnings Conference Call Transcript

    UTHR earnings call for the period ending December 31, 2018.

  • Arena Pharmaceuticals (ARNA) Beats on Q4 Earnings & Revenues
    Zacks20 days ago

    Arena Pharmaceuticals (ARNA) Beats on Q4 Earnings & Revenues

    Arena Pharmaceuticals (ARNA) outpaces earnings estimates in Q4. Also, the top line surpasses the consensus mark. Shares Up.

  • PR Newswire21 days ago

    United Therapeutics Corporation Reports 2018 Fourth Quarter And Annual Financial Results

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Feb. 27, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the fourth quarter and year ...

  • Here's Why MannKind Rocketed Higher Today
    Motley Fool21 days ago

    Here's Why MannKind Rocketed Higher Today

    Shares jumped after the company reported upbeat fourth-quarter results. Here's what investors need to know.

  • Markitlast month

    See what the IHS Markit Score report has to say about United Therapeutics Corp.

    United Therapeutics Corp NASDAQ/NGS:UTHRView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for UTHR with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding UTHR totaled $1.24 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • PR Newswire28 days ago

    United Therapeutics Corporation To Report Fourth Quarter And Annual 2018 Financial Results Before The Market Opens On Wednesday, February 27, 2019

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Feb. 20, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and annual 2018 ...

  • Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for
    Zackslast month

    Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for

    United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Does United Therapeutics Corporation’s (NASDAQ:UTHR) CEO Salary Reflect Performance?
    Simply Wall St.last month

    Does United Therapeutics Corporation’s (NASDAQ:UTHR) CEO Salary Reflect Performance?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Martine Rothblatt became the CEO of UnitedRead More...

  • PR Newswire2 months ago

    Survival Data From FREEDOM-EV Study of Orenitram Presented at the Pulmonary Vascular Research Institute Annual World Congress

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Jan. 31, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that key data from the FREEDOM-EV study of Orenitram® ...

  • GlobeNewswire2 months ago

    Report: Exploring Fundamental Drivers Behind Realty Income, United Therapeutics, NxStage Medical, PTC Therapeutics, AVEO Pharmaceuticals, and Owens & Minor — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Jan. 28, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Intuitive Surgical Earnings, Corbus To Offer Shares, Eton In-Licenses Neurologic Drug

    Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stocks hit 52-week peaks Thursday. Down In The Dumps (Biotech stocks hitting 52-week lows on Jan. 24) Amneal ...

  • PR Newswire2 months ago

    United Therapeutics Announces Closing Of License Agreement With Arena Pharmaceuticals For Ralinepag

    RESEARCH TRIANGLE PARK, N.C., Jan. 24, 2019 /PRNewswire/ -- United Therapeutics Corporation (UTHR) today announced the closing of the transactions contemplated by its license agreement with Arena Pharmaceuticals, Inc. (ARNA). Under the agreement, United Therapeutics acquired exclusive, worldwide rights to develop and manufacture the Phase 3 investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist in development for the treatment of pulmonary arterial hypertension (PAH).  Upon closing, United Therapeutics paid Arena $800 million. As previously announced, the closing of the transactions contemplated by the agreement was conditioned upon expiration or termination of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, among other conditions.

  • Arena Pharmaceuticals Announces Closing of Global License Agreement with United Therapeutics for Ralinepag
    PR Newswire2 months ago

    Arena Pharmaceuticals Announces Closing of Global License Agreement with United Therapeutics for Ralinepag

    SAN DIEGO, Jan. 24, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) today announced the closing of the global license agreement with United Therapeutics Corporation (UTHR) for the Arena-discovered, Phase 3 investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension (PAH).  The global license agreement for ralinepag was announced on November 15, 2018. Ralinepag (APD811) is a next-generation, oral, selective potent, once-daily IP receptor agonist intended for the treatment of pulmonary arterial hypertension (PAH).

  • MoCo economic development officials plan satellite office in Boston
    American City Business Journals2 months ago

    MoCo economic development officials plan satellite office in Boston

    Hey Boston, Montgomery County wants your biotech talent. In an unprecedented move, the Montgomery County Economic Development Corp. is in the early stages of planning an office in the Boston-Cambridge area to recruit companies from the region's rich biotech and life sciences industry. Bob Buchanan, a local developer who chairs the Montgomery County Economic Development Corp., told me Wednesday afternoon the corporation will hire real estate company JLL (NYSE: JLL) to conduct a life sciences market analysis, identify recruitment opportunities and propose potential locations for the office.

  • Did United Therapeutics Corporation (NASDAQ:UTHR) Insiders Sell Shares?
    Simply Wall St.2 months ago

    Did United Therapeutics Corporation (NASDAQ:UTHR) Insiders Sell Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that there are more than a few examples Read More...

  • PR Newswire3 months ago

    United Therapeutics Corporation To Present At 37th Annual J.P. Morgan Healthcare Conference

    SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Dec. 31, 2018 /PRNewswire/ -- United Therapeutics Corporation (UTHR) announced today that Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics, will provide an overview and update on the company's business at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California. The presentation and the immediately following Q&A session will take place on Monday, January 7, 2019, at 2:30 PM Pacific Standard Time, and can be accessed via a live webcast on the United Therapeutics website at http://www.unither.com under the "Investors" tab in the "Events and Presentations" section.